Testing the accelerator hypothesis: A new approach to type 1 diabetes prevention (adAPT 1)

Diabetes, Obesity and Metabolism

Volumn 18, Issue 1, 2016, Pages 3-5

  Wilkin, T ^a   Greene, S ^b   Mccrimmon, R ^b  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METFORMIN; NICOTINAMIDE;

AUTOIMMUNITY; DRUG EFFECT; HISTORY OF MEDICINE; HUMAN; HYPERGLYCEMIA; IMMUNOMODULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PANCREAS ISLET BETA CELL; PRIMARY PREVENTION; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; METABOLISM; ONSET AGE; TIME FACTOR;

ADULT; AGE OF ONSET; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS; TIME FACTORS;

EID: 84954451367     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12599     Document Type: Note

References (30)

1. Bonifacio E. Immunotherapy in type 1 diabetes: a shorter but more winding road. Diabetes 2012; 61: 2214-2215.
2. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14: 619-633.
3. Nerup J, Platz P, Anderssen OO. HL-A antigens and diabetes mellitus. Lancet 1974; 2: 864-866.
4. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2: 1279-1283.
5. Cudworth AG. The aetiology of diabetes mellitus. Br J Hosp Med 1976; 16: 207-216.
6. WHO. Expert Committee on Diabetes Mellitus, Second Report. Geneva: World Health Organization, 1980.
7. Wherrett D, Daneman D. Prevention of type 1 diabetes. Endocrinol Metab Clin N Am 2009; 38: 777-790.
8. Marek-Trzonkowska N, My-Sliwiec M, Dobyszuk A etal. Administration of CD4+CD25 high CD1272 regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care 2012; 5: 1817-1820.
9. Gale EA, Bingley PJ, Emmett CL, Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363: 925-931.
10. Elliott RB, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 34: 362-365.
11. von Herrath M, Nepom GT. Animal models of human type 1 diabetes. Nat Immunol 2009; 10: 129-132.
12. Carel J-C, Boitard C, Eisenbarth GS. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J Autoimmu 1996; 9: 739-745.
13. Øzbay LA, Møller N, Juhl C. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. Brit J Clin Pharmacol 2011; 73: 536-545.
14. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 2001; 44: 914-922.
15. Kushner JA. The role of aging upon β cell turnover. J Clin Invest 2013; 123: 990-995.
16. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
17. Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 2008; 7: 567-573.
18. Tuomi T, Groop LC, Zimmet PZ etal. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359-362.
19. Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes mellitus: "double" diabetes? Pediatr Diabetes 2003; 4: 110-113.
20. Hussen H, Persson M, Moradi T. Maternal overweight and obesity are associated with increased risk of type 1 diabetes in offspring of parents without diabetes regardless of ethnicity. Diabetologia 2015; 58: 1464-1473.
21. Mostazir M, Jeffery A, Voss L, Wilkin T. Childhood obesity: evidence for distinct early and late environmental determinants. A 12-year longitudinal cohort study (EarlyBird 62). Int J Obes (Lond) 2015; 39: 1057-1062.
22. Després JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 1993; 9: 452-459.
23. Metcalf BS, Voss LD, Hosking J etal. Physical activity at the government-recommended level and obesity-related health outcomes: a longitudinal study (Early Bird 37). Arch Dis Child 2008; 93: 772-777.
24. Lamb MM, Frederiksen B, Seifert JA etal. Sugar intake is associated with progression from islet autoimmunity to type 1 diabetes: the Diabetes Autoimmunity Study in the Young. Diabetologia 2015; 58: 2027-2034.
25. Chevalier N, Fénichel P. Endocrine disruptors: new players in the pathophysiology of type 2 diabetes? Diabetes Metab 2015; 41: 107-115.
26. Kodavanti UP. Air pollution and insulin resistance: do all roads lead to Rome? Diabetes 2015; 64: 712-714.
27. Metcalf BS, Hosking J, Frémeaux AE etal. BMI was right all along: taller children really are fatter (implications of making childhood BMI independent of height) EarlyBird 48. Int J Obes (Lond) 2011; 35: 541-547.
28. Scottish Diabetes Survey. 2011. Available from URL: http://www.diabetesinscotland.org.uk/Publications/SDS%202011.pdf. Accessed 5 November 2015.
29. Battaglia M, Atkinson MA. The streetlight effect in type 1 diabetes. Diabetes 2015; 64: 1081-1090.
30. Ziegler A-G, Pflueger M, Winkler C etal. Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J Autoimmun 2011; 37: 3-7.